Charles River (CRL) Expands 3D In Vitro Services Via New Deal
https://www.zacks.com/stock/news/2197217/charles-river-crl-expands-3d-in-vitro-services-via-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197217
Dec 13, 2023 - Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
0
Here's Why You Should Retain McKesson (MCK) Stock for Now
https://www.zacks.com/stock/news/2197165/here-s-why-you-should-retain-mckesson-mck-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197165
Dec 13, 2023 - McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
0
Masimo's (MASI) ORi Favored by Study for PaO2 Information
https://www.zacks.com/stock/news/2196904/masimo-s-masi-ori-favored-by-study-for-pao2-information?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196904
Dec 12, 2023 - Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
0
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
https://www.zacks.com/stock/news/2196894/here-s-why-you-should-retain-surmodics-srdx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196894
Dec 12, 2023 - Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
0
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
https://www.zacks.com/stock/news/2196711/here-s-why-investors-should-retain-resmed-rmd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196711
Dec 12, 2023 - Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.
0
Thermo Fisher (TMO) Launches New Solutions for Clinical Labs
https://www.zacks.com/stock/news/2196649/thermo-fisher-tmo-launches-new-solutions-for-clinical-labs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196649
Dec 12, 2023 - Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.
0
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
https://www.zacks.com/stock/news/2196582/reasons-to-add-cardinal-health-cah-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196582
Dec 12, 2023 - Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
0
Why You Should Retain Merit Medical (MMSI) Stock for Now
https://www.zacks.com/stock/news/2196236/why-you-should-retain-merit-medical-mmsi-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196236
Dec 11, 2023 - Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
0
Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY
https://www.zacks.com/stock/news/2196004/walgreens-wba-alliancerx-pharmacy-will-now-distribute-xdemvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196004
Dec 11, 2023 - Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.
0
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
https://www.zacks.com/stock/news/2195558/amn-healthcare-s-amn-new-tie-up-to-boost-patient-outcome?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195558
Dec 08, 2023 - AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
0